Screening for glaucoma with frequency-doubling technology and Damato campimetry.
OBJECTIVE
To assess frequency-doubling technology (FDT) perimetry (Humphrey Systems, San Leandro, Calif) and Damato campimetry (Precision Vision, Villa Park, Ill) for detecting glaucoma in a public glaucoma screening.


METHODS
A 2-day public glaucoma screening was held at 2 different institutions. Each subject underwent 2 visual field screening tests (Damato campimetry and FDT perimetry in screening mode), an ophthalmologic examination, and Humphrey perimetry (24-2 FASTPAC) for each eye. Eyes were divided into 4 categories: normal, ocular hypertensive, glaucoma suspect, and definite glaucoma. The sensitivity and specificity of FDT perimetry and Damato campimetry for detecting glaucoma were estimated with receiver operating characteristic curves.


RESULTS
Among 240 subjects who underwent FDT, the number identified as normal, ocular hypertensive, glaucoma suspect, and definite glaucoma was 151, 28, 35, and 26, respectively; among 175 subjects who underwent Damato campimetry, the numbers for the same groups were 118, 19, 19, and 19, respectively. The areas under the receiver operating characteristic curve for FDT perimetry and Damato campimetry were 0.925 and 0.883, respectively. The optimal sensitivity and specificity for FDT perimetry were 92% and 93%, while those for Damato campimetry were 53% and 90%, respectively. The average test time was 1 minute and 3 minutes per eye for FDT perimetry and Damato campimetry, respectively.


CONCLUSIONS
Frequency-doubling technology perimetry was superior to Damato campimetry in this screening for glaucoma.
Yamada
N
N
Department of Ophthalmology, University of Washington, Seattle 98195-6485, USA.
Chen
P P
PP
Mills
R P
RP
Leen
M M
MM
Lieberman
M F
MF
Stamper
R L
RL
Stanford
D C
DC
D002140:California / Q000453:epidemiology; D005260:Female; D005901:Glaucoma / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000453:epidemiology; D012372:ROC Curve; D012680:Sensitivity and Specificity; D014786:Vision Disorders / Q000175:diagnosis*; D015351:Vision Screening / Q000379:methods; D058609:Visual Field Tests / Q000379:methods*; D014794:Visual Fields; D014861:Washington / Q000453:epidemiology